3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Neoplasms
2
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Brain Neoplasms
1
Interventions
Capecitabine
13
Fluorouracil
12
Oxaliplatin
9
Nivolumab
9
Radiotherapy
8
Leucovorin
8
Cetuximab
8
Magnetic Resonance Spectroscopy
6
Irinotecan
5
pembrolizumab
4
encorafenib
4
Surgical Procedures, Operative
4
Sigmoidoscopy
4
Radiotherapy, Intensity-Modulated
4
Surveys and Questionnaires
3
Standard of Care
3
Specimen Handling
3
Biopsy
3
Bevacizumab
3
dostarlimab
2
dehydroftorafur
2
atezolizumab
2
XELOX
2
X-Rays
2
Observation
2
Magnetic Resonance Imaging
2
Immunoglobulin G
2
Folfox protocol
2
Drug Therapy
2
Disulfides
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Rectal Neoplasms
×
adagrasib
×
Clear all
NCT04793958
2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3
Active not recruiting
461 enrolled